{"drugs":["Apremilast","Otezla"],"mono":{"0":{"id":"930920-s-0","title":"Generic Names","mono":"Apremilast"},"1":{"id":"930920-s-1","title":"Dosing and Indications","sub":[{"id":"930920-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Plaque psoriasis, Moderate to severe, in candidates for phototherapy or systemic therapy:<\/b> Initial titration over 5 days: Day 1, 10 mg ORALLY in AM; Day 2, 10 mg ORALLY twice daily; Day 3, 10 mg in AM, 20 mg in PM; Day 4, 20 mg ORALLY twice daily; Day 5, 20 mg in AM, 30 mg in PM; do not crush, split, or chew<\/li><li><b>Plaque psoriasis, Moderate to severe, in candidates for phototherapy or systemic therapy:<\/b> Maintenance: Day 6 and thereafter, 30 mg ORALLY twice daily; do not crush, split, or chew<\/li><li><b>Psoriatic arthritis, Active:<\/b> Initial titration over 5 days: Day 1, 10 mg ORALLY in AM; Day 2, 10 mg ORALLY twice daily; Day 3, 10 mg in AM, 20 mg in PM; Day 4, 20 mg ORALLY twice daily; Day 5, 20 mg in AM, 30 mg in PM; do not crush, split, or chew<\/li><li><b>Psoriatic arthritis, Active:<\/b> Maintenance: Day 6 and thereafter, 30 mg ORALLY twice daily; do not crush, split, or chew<\/li><\/ul>"},{"id":"930920-s-1-5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"930920-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, severe (estimated CrCl less than 30 mL\/min by the Cockroft-Gault equation):<\/b> initiate dose with 10 mg ORALLY once daily for 3 days, 20 mg ORALLY once daily on days 4 and 5, and then 30 mg ORALLY once daily on day 6 and thereafter<\/li><li><b>hepatic impairment:<\/b> no dosage adjustments needed<\/li><\/ul>"},{"id":"930920-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Plaque psoriasis, Moderate to severe, in candidates for phototherapy or systemic therapy<\/li><li>Psoriatic arthritis, Active<\/li><\/ul>"}]},"3":{"id":"930920-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930920-s-3-9","title":"Contraindications","mono":"hypersensitivity to apremilast or any component of the product <br\/>"},{"id":"930920-s-3-10","title":"Precautions","mono":"<ul><li>coadministration with strong CYP450 inducers; use is not recommended<\/li><li>depression has been reported during therapy; increased risk with history of depression, suicidality, or both; consider discontinuation if symptoms occur<\/li><li>renal impairment, severe (estimated CrCl 0 to 30 mL\/min by the Cockroft-Gault equation); dose reduction required<\/li><li>weight loss, clinically significant, has been reported; monitoring recommended; treatment discontinuation may be required<\/li><li>suspected adverse reactions; report to US Food and Drug Administration at 1-800-FDA-1088, or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"930920-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"930920-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930920-s-4","title":"Drug Interactions","sub":{"1":{"id":"930920-s-4-14","title":"Major","mono":"<ul><li>Carbamazepine (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><\/ul>"}}},"5":{"id":"930920-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Diarrhea (Psoriasis, 17%; psoriatic arthritis, 7.7% to 9.3%), Nausea (Psoriasis, 17%; psoriatic arthritis, 7.4% to 8.9%)<\/li><li><b>Neurologic:<\/b>Headache (4.8% to 6%), Tension-type headache (Psoriasis, 8%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Weight decreased (10% to 12%)<\/li><li><b>Psychiatric:<\/b>Depression (1% to 1.3%), Suicidal behavior, Suicidal thoughts<\/li><\/ul>"},"6":{"id":"930920-s-6","title":"Drug Name Info","sub":{"0":{"id":"930920-s-6-17","title":"US Trade Names","mono":"Otezla<br\/>"},"2":{"id":"930920-s-6-19","title":"Class","mono":"<ul><li>Musculoskeletal Agent<\/li><li>Phosphodiesterase Inhibitor<\/li><\/ul>"},"3":{"id":"930920-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"930920-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"930920-s-7","title":"Mechanism Of Action","mono":"Apremilast, is a phosphodiesterase 4 (PDE4) inhibitor, with specificity for cyclic adenosine monophosphate (cAMP) that results in increased intracellular cAMP levels. The exact mechanism in psoriatic arthritis is not well defined.<br\/>"},"8":{"id":"930920-s-8","title":"Pharmacokinetics","sub":[{"id":"930920-s-8-23","title":"Absorption","mono":"<ul><li>Bioavailability, Oral: 73%<\/li><li>Tmax, Oral: 2.5 hours<\/li><li>Effects of food: no effect on absorption<\/li><\/ul>"},{"id":"930920-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 68%<\/li><li>Vd: 87 L<\/li><\/ul>"},{"id":"930920-s-8-25","title":"Metabolism","mono":"<ul><li>Metabolite M12: inactive, plus up to 23 metabolites identified in the plasma, urine, and feces<\/li><li>Substrate of CYP3A4, CYP1A2, CYP2A6, and P-glycoprotein<\/li><\/ul>"},{"id":"930920-s-8-26","title":"Excretion","mono":"<ul><li>Renal excretion: 3% unchanged<\/li><li>Fecal excretion: 7% unchanged<\/li><li>Total body clearance: 10 L\/hr<\/li><\/ul>"},{"id":"930920-s-8-27","title":"Elimination Half Life","mono":"6 to 9 hours <br\/>"}]},"9":{"id":"930920-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may administer without regard to food<\/li><li>do not crush, split, or chew tablets<\/li><\/ul>"},"10":{"id":"930920-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement of psoriatic arthritis is indicative of efficacy<\/li><li>patient weight; during treatment<\/li><\/ul>"},"11":{"id":"930920-s-11","title":"How Supplied","mono":"<b>Otezla<\/b><br\/>Oral Tablet: 30 MG<br\/>"},"13":{"id":"930920-s-13","title":"Clinical Teaching","mono":"<ul><li>Tell patient to report any unintentional weight loss<\/li><li>Side effects may include headache, diarrhea, or nausea.<\/li><li>Instruct patient to report worsening depression, suicidal ideation, or unusual changes in behavior.<\/li><\/ul>"}}}